文献速递艾滋病与性传播感染

使用替诺福韦二磷酸水平预测人类免疫缺陷病毒(HIV)感染女性产后病毒血症:一项巢式病例对照研究

Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
PubMed 文献 · Clin Infect Dis · 2022-01-01

在产后抗逆转录病毒治疗(ART)策略试验中开展巢式病例对照研究,61例病例和20例对照贡献365对干血斑-病毒载量样本;替诺福韦二磷酸(TFV-DP)<700 fmol/punch预测未来病毒血症的敏感度为62.9%、特异度为89.7%;调整后TFV-DP 350-699和<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比分别为3.5和12.9;作者认为TFV-DP与未来病毒血症强相关,似有助于识别不依从并预测未来病毒载量升高。

要点

  • 产后HIV感染女性中,TFV-DP<700 fmol/punch预测未来病毒血症的敏感度62.9%、特异度89.7%。
  • 调整后TFV-DP 350-699 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为3.5。
  • 仅分析病毒抑制期样本时,TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为9.5。

核心结论

  • 干血斑中TFV-DP浓度与未来病毒血症强相关,作者认为似有助于识别不依从并预测未来病毒载量升高。

研究设计与样本

  • 在产后ART给药策略试验内开展巢式病例对照研究;参与者妊娠期开始含替诺福韦二酯(TDF)的ART,产后<10周且病毒载量<400 copies/mL。
  • 病毒载量和TFV-DP样本每3-6个月采集一次,共24个月;病例为≥1次病毒载量≥20 copies/mL者,对照从持续病毒抑制(病毒载量<20 copies/mL)女性中随机抽取。
  • 共61例病例和20例对照,贡献365对干血斑-病毒载量样本,中位ART时长16个月。

主要发现

  • TFV-DP<700 fmol/punch检测未来病毒血症的敏感度为62.9%(95% CI,54.7-70.6%),特异度为89.7%(95% CI,84.9-93.4%)。
  • 调整年龄、ART时长、既往病毒载量及TFV-DP与病毒载量检测间隔后,TFV-DP 350-699 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为3.5(95% CI,1.1-10.8;P = .033)。
  • 调整后TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为12.9(95% CI,3.6-46.6;P < .0001)。
  • 仅纳入病毒抑制期样本时,TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为9.5(95% CI,1.9-47.0)。

临床怎么用

  • 作者认为干血斑TFV-DP浓度似有助于识别不依从并预测未来病毒载量升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART). METHODS: We conducted a nested case-control study within a trial of postpartum ART delivery strategies. Participants started ART containing tenofovir disoproxil fumarate (TDF) in pregnancy, were <10 weeks postpartum, and had a VL <400 copies/mL. VL and TFV-DP samples were taken every 3-6 months over 24 months. Cases had ≥1 VL ≥20 copies/mL; controls were randomly sampled from women with persistent viral suppression (VS; VL <20 copies/mL). Generalized estimating equations were used to calculate likelihood odds ratios (LORs) for future VL ≥20 copies/mL by TFV-DP concentration at the preceding visit. RESULTS: 61 cases and 20 controls contributed 365 DBS-VL pairs (median ART duration, 16 months). Sensitivity and specificity of TFV-DP <700 fmol/punch to detect future viremia were 62.9% (95% CI, 54.7-70.6%) and 89.7% (84.9-93.4%), respectively. Adjusting for age, ART duration, previous VL, and duration between the TFV-DP and VL measures, LORs of viremia for TFV-DP concentrations 350-699 and <350 fmol/punch versus TFV-DP ≥1850 fmol/punch were 3.5 (95% CI, 1.1-10.8; P = .033) and 12.9 (3.6-46.6; P < .0001), respectively. Including only samples taken during VS, the LOR of future viremia for TFV-DP concentration <350 fmol/punch versus TFV-DP ≥1850 fmol/punch was 9.5 (1.9-47.0). CONCLUSIONS: TFV-DP concentrations in DBSs were strongly associated with future viremia and appear useful to identify nonadherence and predict future elevated VL.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Odayar J, Orrell C, Phillips TK, et al. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. Clin Infect Dis. 2022. PMID: 34979553. doi:10.1093/cid/ciab1068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。